Clinical Trials Logo

HER2-ve Metastatic Breast Cancer clinical trials

View clinical trials related to HER2-ve Metastatic Breast Cancer.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03286842 Completed - Clinical trials for HER2-ve Metastatic Breast Cancer

To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.

Start date: January 17, 2018
Phase: Phase 3
Study type: Interventional

This open-label, multi-centre phase IIIb study will assess the effectiveness, benefits and potential harms in the use of olaparib monotherapy treatment for patients with HER2-ve metastatic breast cancer associated with germline or somatic breast cancer susceptibility gene (gBRCA1/2 or sBRCA1/2) mutations.